Introduction: The dynamics of prostate specific antigen (PSA) in patients who have prostate cancer and receive radiotherapy is a very interesting but complicated topic. We tried to plot the sequential changes of PSA with and without hormone therapy and tried to find out the predictors for the high-risk patients for prostate cancer recurrence. Methods: We reviewed the medical records of 164 prostate cancer patients who underwent intensitymodulated radiation therapy (IMRT) as the primary treatment. We recorded the patients' age, initial PSA, cancer grading at diagnostic biopsies (Gleason's score), clinical stage, the IMRT dosage, neoadjuvant, concomitant, and prolonged hormone therapy, follow-up PSA levels, biochemical progression, and distant metastasis. Results: Of the 84 patients undergoing radiotherapy for prostate cancer with complete data for analysis, the biochemical failure-free survival (BFFS) rate was 88.09%. The patients with an initial PSA of less than 10 ng/mL had the best BFFS. Of the patients receiving neoadjuvant hormone therapy (NHT), serum PSA levels were significantly higher in those with biochemical failure than those without biochemical failure in the 3 months after radiation therapy. As for the patients free of biochemical failure, the mean PSA fell below 1 ng/mL immediately after IMRT for the NHT(þ) group and at 9 months after IMRT for the NHT(e) group. Conclusion: For the patients with localized prostate cancer who underwent IMRT, initial PSA could predict clinical stage, 1-year BFFS, and 2-year BFFS. The follow-up PSA, as early as 3 months, was of clinical predictive value.
Introduction
The combination of prostate specific antigen (PSA) and digital rectal examination has been proposed as less costly and more specific with equal sensitivity to early prostate cancer detection. 1 PSA, a member of the kallikrein-type serine protease family, abundant both in benign and malignant prostate tissue, was introduced as an organ-specific serum biomarker for prostate cancer in the 1980s. 2 Although PSA was developed as a screening tool, it is also an ideal surrogate marker for the follow-up of treatment effects and evaluation of prognoses. Freedland et al 3 documented that PSA levels at diagnosis could be effective in predicting prostate cancer prognosis after radical prostatectomy. We were inspired by their article to study whether the predictive value of PSA also exists in biochemical failure (BF) and distant metastasis (DM) of the patients undergoing external radiation therapy for prostate cancer.
The dynamics of PSA after radiation therapy is a very interesting and complicated topic because the applications of neoadjuvant, concurrent, and prolonged hormone therapy could all affect serum PSA levels. 4 In this study, we made efforts to plot the sequential changes of PSA with and without hormone therapy and tried to find early cutoff points for the high-risk patients to receive salvage intervention.
Methods
After obtaining Institutional Review Board approval, we searched for the keyword "prostate cancer" in the National Taiwan University Hospital Cancer Registration Database between January 2002 and December 2006. Of the 1076 patients retrieved from the database, there were 164 patients receiving external radiation therapy with definitive intensity-modulated radiotherapy (IMRT) as the primary treatment with or without neoadjuvant hormone therapy. After excluding the patients with metastasis at diagnosis, incomplete PSA data, or loss of follow-up, 84 patients were included in the study for further analysis. IMRT was delivered in conjunction with image-guided radiation therapy. 5 As described in the article by Wang et al, 5 all patients were treated with 10-MV photon beams from a Siemens Primus or Elekta Synergy linear accelerator. The margins for planning target volume were 0.6 cm in the posterior direction and 1.0 cm in other directions. During each treatment, patients were placed in a prone position in a vacuum bag for torso immobilization, and with an endorectal balloon inserted and then inflated with 60 mL of air for prostate immobilization and rectum sparing. The PSA level was followed every 3 months after radiotherapy. We reviewed the data of the patients, including the patients' age, initial serum PSA concentration, cancer grading at diagnostic biopsies, clinical stage (defined by digital rectal examination), the IMRT dosage, neoadjuvant, concomitant, and prolong hormone therapy, and follow-up PSA levels. A biochemical progression was defined as a single PSA elevation of 2 ng/mL or three persistent PSA elevations. 6 Metastasis was defined with positive findings from whole body bone scan, computed tomography, or chest X-ray. Preradiotherapy serum PSA, postradiotherapy serum PSA (PSA0), PSA nadir, and postradiotherapy serum PSA at 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months (PSA3, PSA6, PSA9, PSA12, PSA18, and PSA24) were recorded. Neoadjuvant hormonal androgen deprivation therapy (NHT) started 1e3 months prior to the initiation of IMRT. The regimens included Cyproterone acetate (Androcur), Bicalutamide (Casodex), Flutamide (Fugerel), Leuprolide acetate (Leuplin), or Triptorelin (Decapeptyl CR). NHT was given with the intention of controlling the disease extent, decreasing the prostate volume, and potentially facilitating the delivery of escalated radiation dose. Chi-square test and Student t test were used for statistical analysis.
Results
Of the 84 patients enrolled for data analysis, the median dose to the clinical target volume was 78.3 Gy (range, 70.00e81.51 Gy) in 39 daily fractions of 1.79e2.09 Gy over 8 weeks. The patients' characteristics, including patients' age, initial serum PSA, percentage of free PSA, Gleason sum, and clinical stage are summarized in Table 1 .
The follow-up duration ranged from 2.03 years to 6.12 years with a mean of 3.65 years. The 2-year overall survival rate was 100%. However, one patient died of cardiovascular disease 2.6 years after IMRT, and two patients died of prostate cancer 2.3 years and 3.2 years after IMRT, respectively. The 2-year biochemical failurefree survival (BFFS) rate was 88.09%. The 2-year distant metastasis-free survival (DMFS) rate was 95.2%. One patient was noted to have bone metastasis 2.7 years after radiation therapy.
After subgrouping, the patients with their initial serum PSA at diagnosis, clinical stage, pathological features, BFFS, and DMFS rate are listed in Table 2 . Initial serum PSA has a statistically significant predictive value in terms of clinical stage, 1-year BFFS, 2-year BFFS, and 2-year DMFS.
Serum PSA levels at diagnosis, prior to radiation therapy, and at 0 months, 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months after IMRT are listed according to the presence or absence of BF and DM in Table 3 . Of the patients receiving neoadjuvant hormone therapy, serum PSA levels were significantly higher in the BF(þ) group than in the BF(e) group 3 months after radiation therapy. Of the patients without neoadjuvant hormone therapy, serum PSA levels were always higher in the BF(þ) group. More specifically, the 3-month PSA was 1.46 ng/mL and 0.46 ng/mL (p ¼ 0.027) for NHT(þ) BF(þ) and NHT(þ)BF(e), respectively. The 3-month PSA was 26.35 ng/ mL and 1.48 ng/mL for NHT(e)BF(þ) and NHT(e)BF(e), respectively. As for the patients free of BF, the mean PSA fell below 1 ng/mL immediately after radiation therapy for the patients with neoadjuvant hormone therapy, and the mean PSA fell below 1 ng/mL at 9 months after radiation therapy for the patient without NHT.
Discussion
According to the guidelines of prostate cancer treatment, patients with localized prostate cancer should be informed of the treatment options, including active surveillance, radiotherapy (external beam and interstitial radiation therapy), and radical prostatectomy. 7 External beam radiation therapy is the treatment choice for most men with early-stage prostate cancer. Unlike The modern radiation modality, an advancement from 3D conformal treatment, is believed to reduce rectal injury in comparison with conventional radiotherapy and to enhance the conformality of the dose distribution around the tumor target. 9 Comparing the patients' characteristics of our institution with the data from New York, the patients receiving IMRT in Taiwan tend to have higher proportions of PSA greater than 20 (36.9% vs. 8%) and stage T3 cancer (46.4% vs. 6%). This could be attributable to the prostate cancer screening program or the patients' attitudes toward radiotherapy. We need further epidemiological studies to clarify the condition. PSA is widely used as a detecting, diagnosing, prognosis determining, and clinical decision making biomarker for prostate cancer. Since its discovery in 1979, PSA has not only been used as a screening tool, but also as a predictor of prostate tumor volume, stage, and prognosis. 10 Freedland et al 3 have proposed that the higher preoperative PSA levels of the patients receiving radical prostatectomy could predict extracapsular extension, positive surgical margins, seminal vesicle invasion, pathological stage, and biochemical progression. After subgrouping initial PSA at diagnosis, we also noted that the clinical stage, BF, and DM rate increased significantly with PSA elevation. There are various definitions of BF following radiotherapy, which might not completely correlate with clinical results. 6 We adopted the same criteria used by Zelefsky et al. 9 A PSA relapse was defined according to the American Society for Radiation Oncology (ASTRO) consensus definition (3 successive PSA increases after a posttreatment nadir was achieved) 11 and according to the Houston definition (absolute nadir plus 2 ng/mL dated at the call). 12 They reviewed 561 patients with localized prostate cancer treated by IMRT. The 8-year PSA relapse-free survival rates for favorable, intermediate, and unfavorable groups were 85%, 76%, and 72%, respectively. DM developed in 3%. T stage greater than T2c and pretreatment PSA greater than 10 ng/mL had significantly higher risk for PSA relapse. Overall, 2-year BFFS and 2-year DMFS of the patients who underwent IMRT because of localized prostate cancer were 76.2% and 95.2%, respectively, in our study. Long-term prognosis still needs further evaluation. Two-year BFFS, and 1-year and 2-year DMFS were all significantly decreased with higher pretreatment PSA. PSA nadir could predict biochemical recurrence after external radiation beam therapy for prostate cancer. A PSA nadir of 0.5 ng/ mL or less represents an early endpoint strongly predictive of a favorable outcome following radiation therapy. 13 It is time consuming to identify the absolute PSA nadir. Thus, Alcantara et al came up with an idea regarding the nadir PSA within 12 months after radiation therapy (nPSA12), in which they used 2 ng/mL as a cutoff point. The 5-year BF rates for the patients with an nPSA12 >2 and <2 ng/mL were 36% and 26%, respectively (p ¼ 0.0015). An nPSA12 >2 ng/mL was associated with a 4-fold risk of DMF. 14 We meticulously examined the 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months PSA levels after radiation therapy and subgrouped the patients into patients with and without neoadjuvant hormone therapy. The NHT(þ) and NHT(e) groups were both divided according to the presence of BF or DM. As for the NHT(þ) group, the PSA levels began to present statistically significant difference between the BF(þ) and BF(e) groups 3 months after radiotherapy. For the NHT(e) group, the PSA levels had a significant difference between the BF(þ) and BF(e) groups with the pretreatment initial PSA and all further PSA levels. The same trend was also noted in the analysis of DM.
Notably, in the NHT(e) group, BF(þ) and DM(þ) patients had their PSA0 > PreRT PSA. One possible explanation is that micrometastasis, which could not be detected by imaging studies, could have happened prior to the initiation of radiotherapy, thus resulting in PSA0 > PreRT PSA. Nonetheless, PSA0 > PreRT PSA could be a predictor for BF(þ) or DM(þ) in NHT(e) patients. Another distinct finding is that the initial serum PSA concentration was always higher than PreRT PSA in the NHT(e) group. Because of the small sample size, the PSA value could be largely affected by some specific individuals who might have experienced concurrent infection, laboratory error, or even alternative treatment beyond our monitoring scope. A larger study is needed to clarify this situation.
The mean PSA of NHT(e)BF(þ) and NHT(e)BF(e) 12 months after radiotherapy were 4.43 ng/mL and 0.62 ng/mL, respectively. The finding is consistent with the cutoff point 2 ng/mL set by Alcantara et al. 15 However, the mean PSA of NHT(þ)BF(þ) and NHT(þ)BF(e) 12 months after radiotherapy was 1.52 ng/mL and 0.28 ng/mL, respectively. The finding suggested that a lower cutoff value of nPSA 12 could be proposed for patients with neoadjuvant hormone therapy. We did not compare the effects of treatment with NHT and without NHT because the mean PSA of the two groups are far too different in the first place. The topic might be investigated in a further multicentered database. The major limitations of our study are the limited case numbers and the variability of androgen deprivation therapy and follow-up methods between each physician. There is a relatively low incidence of prostate cancer in Taiwan, and the patients' characteristics are not identical to those of the patients in Western countries. 16 Although the case numbers in this study are limited, our results presented the predictive value of PSA for the Taiwan male with prostate cancer undergoing IMRT with or without NHT, and they also showed the PSA dynamic changes after IMRT. The association of pretreatment PSA and BF after radiotherapy is documented in previous studies and is well accepted. 17, 18 The use of PSA dynamics as a marker needs to take into account its dependence on pretreatment variables. Further prospective studies could be conducted to obtain an appropriate follow-up PSA cutoff point to treat the patients with higher risk of disease progression earlier.
In conclusion, for patients with localized prostate cancer undergoing IMRT, pretreatment initial PSA could predict clinical stage, 1-year BFFS, 2-year BFFS, and 2-year DMFS. The PSA levels at 3 months after radiotherapy was significantly different between the NHT(þ)BF(þ) and NHT(þ)BF(e) groups, which is of predictive value for further salvage intervention.
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